Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mandy Jackson

Mandy Jackson is the US West Coast Editor for Scrip Intelligence. Mandy reports on daily biopharma news and regularly interviews everyone from big pharma CEOs to biotech startup founders about the business strategy behind their finance, dealmaking and drug development news. She also has an interest in drug pricing and novel reimbursement strategies, new treatments in areas of true unmet need, and business development trends. Mandy has been a business news reporter for more than 15 years, covering biotech and pharma companies, biotech law and commercial real estate. She is based in San Diego, California – the venue for many medical and biopharma industry meetings.
Advertisement
Set Alert for Articles By Mandy Jackson

Latest From Mandy Jackson

Gilead Partners With Sangamo For Gene Editing As It Builds Up Kite's Cell Therapy Platform

Gilead committed more than $3bn via its subsidiary Kite to license Sangamo's zinc finger technology for gene editing that may deliver improved T cell therapies for cancer. More deals are expected in this space as Gilead builds its cell therapy platform after buying Kite last year.
Deals Business Strategies

AAD Roundup: Sun Sets Sights On Psoriasis As Competitive Pressures Mount

Sun presented new data on its IL-23 inhibitor tildrakizumab, pending US FDA approval, at the American Academy of Dermatology meeting. Novartis and others – all competing for payers' dollars – also try to make the case for their products.

Dermatology Research and Development Strategies

AAD Roundup: More Data Emerges In Atopic Dermatitis, But Dupixent Maintains Big Lead

Atopic dermatitis (AD) was a hot topic at the AAD meeting based on last year's Dupixent approval and the growing array of new systemic and topical therapies for the skin condition – and the large market those products may address.

Clinical Trials Research and Development Strategies

A First For Prostate Cancer: Janssen's Erleada Approved For Non-Metastatic Patients

J&J subsidiary Janssen's Erleada (apalutamide) is the first therapy approved for non-metastatic castration-resistant prostate cancer (nmCRPC). The US FDA decision came about two months early, but the drug – priced at $10,920 per month, or $131,040 annually – may soon face competition.
Approvals Cancer

Workforce Roundtable Part 3: Diversity And Progress – And Advice For Biopharma's Next Generation

Women in leadership roles has become a much discussed issue for the biopharma industry, but less attention seems to be focused on racial diversity. Scrip's panel talks about challenges and opportunities, and offers advice for next generation employees.

Human Capital Leadership

Sandoz's Less Frequently Dosed Copaxone Generic Glatopa Hits Teva Two Months Early

Teva said its 2018 revenue guidance reflected an April launch for the 40 mg dose of Glatopa, but Sandoz and partner Momenta announced FDA approval and the US launch of their less frequently administered Copaxone generic on Feb. 13.
Generic Drugs Approvals
See All
Advertisement
UsernamePublicRestriction

Register